Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Concetta Fargnoli

Showing results (191-200 of 284) with videos related to

Pageof 29
Sort By:
Clinical, Cosmetic and Investigational Dermatology|April 10, 2023
Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME StudyMarina Talamonti, Filomena Russo, Giovanna Malara, et al.
Dermatology and Therapy|January 23, 2025
Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian StudyFederico Diotallevi, Maria Esposito, Maria Concetta Fargnoli, et al.
Dermatology Practical & Conceptual|March 30, 2026
A Risk-Scoring Classifier for the Diagnosis and Management of Atypical Melanocytic Lesions of the Palms: the iDScore_palmar ModelLinda Tognetti, Sofia Lo Conte, Chiara Miracapillo, et al.
Dermatology Practical & Conceptual|November 14, 2025
GRINCH Index: Measuring Patient Satisfaction During Christmas Holiday Gift ProgramsGiulio Gualdi, Laura Bigi, Clara De Simone, et al.
Psoriasis (Auckland, N.Z.)|September 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Expert Opinion on Biological Therapy|June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 yearMarco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
The Journal of Investigative Dermatology|July 30, 2013
Association of genetic variants in CDK6 and XRCC1 with the risk of dysplastic nevi in melanoma-prone familiesXueying Liang, Ruth M Pfeiffer, Wen-Qing Li, et al.
Dermatology (Basel, Switzerland)|November 2, 2023
Molecular Profile of Subungual Melanoma: A MelaNostrum Consortium Study of 68 Cases Reporting BRAF, NRAS, KIT, and TERT Promoter StatusDavid Millan-Esteban, Zaida García-Casado, Anna Macià, et al.
Dermatology and Therapy|April 16, 2025
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Clinical and Experimental Dermatology|April 16, 2025
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Pageof 29

Showing results (191-200 of 284) with videos related to

Sort By:
Pageof 29
Clinical, Cosmetic and Investigational Dermatology|April 10, 2023
Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME StudyMarina Talamonti, Filomena Russo, Giovanna Malara, et al.
Dermatology and Therapy|January 23, 2025
Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian StudyFederico Diotallevi, Maria Esposito, Maria Concetta Fargnoli, et al.
Dermatology Practical & Conceptual|March 30, 2026
A Risk-Scoring Classifier for the Diagnosis and Management of Atypical Melanocytic Lesions of the Palms: the iDScore_palmar ModelLinda Tognetti, Sofia Lo Conte, Chiara Miracapillo, et al.
Dermatology Practical & Conceptual|November 14, 2025
GRINCH Index: Measuring Patient Satisfaction During Christmas Holiday Gift ProgramsGiulio Gualdi, Laura Bigi, Clara De Simone, et al.
Psoriasis (Auckland, N.Z.)|September 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Expert Opinion on Biological Therapy|June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 yearMarco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
The Journal of Investigative Dermatology|July 30, 2013
Association of genetic variants in CDK6 and XRCC1 with the risk of dysplastic nevi in melanoma-prone familiesXueying Liang, Ruth M Pfeiffer, Wen-Qing Li, et al.
Dermatology (Basel, Switzerland)|November 2, 2023
Molecular Profile of Subungual Melanoma: A MelaNostrum Consortium Study of 68 Cases Reporting BRAF, NRAS, KIT, and TERT Promoter StatusDavid Millan-Esteban, Zaida García-Casado, Anna Macià, et al.
Dermatology and Therapy|April 16, 2025
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Clinical and Experimental Dermatology|April 16, 2025
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Pageof 29